Association between adenoma location and risk of recurrence by Pohl, Heiko et al.
Association between adenoma location and risk of recurrence
Heiko Pohl1,2, Douglas J. Robertson1,2, Leila A. Mott3, Dennis J. Ahnen4, Carol A. Burke5, 
Elizabeth L. Barry3, Robert S. Bresalier6, Jane C. Figueiredo7, Aasma Shaukat8, Robert S. 
Sandler9, and John A. Baron9
1Department of Gastroenterology, VA Medical Center, White River Junction, VT
2Geisel School of Medicine at Dartmouth, Lebanon, NH
3Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH
4Department of Medicine, University of Colorado, Denver, CO
5Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH
6Department of Gastroenterology, MD Anderson Cancer Center, Houston, TX
7Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 
Los Angeles CA
8Section of Gastroenterology, Minneapolis VAHCS and University of Minnesota, Minneapolis, MN
9Department of Medicine, University of North Carolina, Chapel Hill, NC
Abstract
Background and Aims—The biological environment varies across the colorectum and may 
therefore differently affect neoplastic growth in the proximal and distal colon. The aim of the 
study was to evaluate the risk for recurrent adenomas and their anatomic location based on 
adenoma location at baseline colonoscopy.
Methods—Data were extracted from three adenoma prevention trials (n= 2430). Participants had 
at least one adenoma at baseline colonoscopy and underwent subsequent surveillance colonoscopy, 
at which time metachronous adenomas could be detected. We calculated the risk ratio (RR) and 
the 95% confidence interval (CI) for metachronous adenomas by location of the baseline lesion 
and considered the impact of advanced neoplasia and multiplicity.
Results—At baseline 522 subjects (21.5%) had adenomas only in the proximal colon, 1266 
subjects (52.1%) had adenomas only in the distal colorectum and 642 (26.4%) had adenomas in 
both regions. Overall 877 subjects (36.5%) had metachronous adenomas during the follow-up 
period. Those with only proximal adenomas at baseline had a higher risk of metachronous 
adenomas compared to subjects with only distal adenomas (RR 1.17, 95% CI 1.01–1.35). A 
greater proximal risk was found after restricting the analysis to subjects with multiple proximal 
adenomas versus multiple distal adenomas (RR 1.35, 95% CI 1.10–1.67). The risk of recurrent 
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adenomas on the same side was 48% higher for subjects with only proximal adenomas at baseline 
compared to those with only distal adenomas at baseline (RR 1.48, 95% CI 1.22–1.80).
Conclusions—Patients with proximal adenomas only have a modestly greater risk of adenoma 
recurrence than patients with adenomas limited to the distal colon, as well as a greater likelihood 
of adenoma recurrence on the same side compared to subjects with distal adenomas. This 
observation suggests that biological factors may differentially affect neoplasia growth across the 
colon.
Keywords
Colonoscopy; polyps; recurrence
Introduction
It is well recognized that colorectal cancers (CRC) differ in their epidemiological and 
molecular characteristics in their location throughout the colorectum,1 suggesting different 
pathways to cancer2. For instance, the frequency of cancers with CIMP (CpG island 
methylator) phenotype or those with a BRAF mutation gradually increase from the distal to 
the proximal colorectum3. A CIMP phenotype is often associated with mismatch repair gene 
hypermethylation, which results in microsatellite instability. The proportion of cancers with 
microsatellite instability is correspondingly greater in the proximal colon4–6. A recent study 
suggests that proximal and distal adenomas express distinct DNA methylation patterns7 
suggesting that carcinogenesis may differ by location in the colon.
The proximal colon and the distal colon differ in their embryologic development and various 
luminal and mucosal characteristics. These include morphological qualities (e.g. mucosal 
capillary network, crypt length), biochemical features (e.g. fatty acid production), 
physiological processes (e.g. microbiome variation, secondary bile acid metabolism, 
bacterial mutagenic metabolites, apoptotic index), and differences in stool consistency8–11. 
These characteristics reflect a different biologic environment along the large intestine and a 
varying milieu at the mucosal-luminal interface. Because the milieu may foster or impede 
carcinogenesis12, it is possible that adenomas in the proximal and distal colon may vary in 
their risk of recurrence.
In this study, we aimed to determine whether risk of metachronous adenomas and their 
anatomic location vary by the proximal versus distal location of baseline lesions. We 
analyzed the association between the baseline location of adenomas and subsequent risk of 
metachronous adenomas, the effect of multiplicity on this association, and whether the side 
of adenoma location is associated with the location of recurrent adenomas.
Methods
Participants
Data on participants from three multicenter randomized chemoprevention trials were used 
for the current analysis. Details of the study designs and principal findings have been 
reported previously13–15. The Anti-Oxidant Polyp Prevention Study14 examined the effect of 
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beta-carotene, vitamins C, and E on adenoma recurrence. The trial randomized 864 subjects 
into four treatment arms in a factorial design from 1985 to 1988. The Calcium Polyp 
Prevention Study was a similar trial of the effect of Calcium supplementation15. It 
randomized 930 subjects into two treatment arms from 1988 to 1992. The Aspirin-Folate 
Polyp Prevention Study examined two different doses of Aspirin (81 mg and 325 mg) and 
Folate (1 mg). This factorial trial randomized 1121 subjects into three Aspirin treatment 
arms and 1021 subjects into two Folate treatment arms from 1994 to 1998.
The trials enrolled adults between the ages of 21 and 80 years, who had at least one 
adenomatous polyp detected within three months prior to enrollment into the first two 
trials13, 14 and up to sixteen months prior to enrollment into the Aspirin/Folate trial15. 
Information regarding the size, location and histology of these polyps was obtained from 
endoscopy and pathology reports. All participants were considered clear of adenomas on the 
basis of a complete colonoscopy within 3 months prior to study entry. Subjects with a 
history of colorectal cancer or Familial Adenomatous Polyposis, or with a detected cancer at 
the entry examination were excluded. An additional clearing colonoscopy was performed 
after one year in the first two trials.
We defined the study entry colonoscopy and the one-year clearing examination together as 
the “baseline colonoscopy” in the first two trials13, 14 and the entry colonoscopy as the 
baseline colonoscopy in the third trial15. Follow-up colonoscopy examinations in the first 
two trials were performed after four years, and in the third trial after three years following 
the baseline clearing exams. All polyps identified during follow up were removed. 
Information about the size and location of each lesion was abstracted from the endoscopy 
and pathology reports at the time of each trial. In addition, during each trial, all removed 
tissue underwent central review by a single study pathologist. Polyps were judged as 
adenomatous or non-adenomatous (e.g. hyperplastic). At the time of the three polyp 
prevention trials, non-dysplastic serrated polyps were typically considered to be 
hyperplastic. Therefore, all serrated polyps at baseline or follow-up examination were 
considered non-neoplastic and not included in the analysis.
Analysis
Our primary objective was to determine the risk of metachronous adenomas based on the 
location of adenomas at baseline colonoscopy. Proximal adenomas were defined as 
adenomas occurring proximal to the splenic flexure, and distal adenomas were defined as 
those at or distal to the splenic flexure. We defined metachronous adenomas as all adenomas 
that were detected during follow-up – up to and including the four-year colonoscopy in the 
first two trials and the three-year colonoscopy in the third trial. Advanced adenomas were 
defined conventionally as adenomas ≥10mm or with advanced histological characteristics 
(tubulovillous or villous adenomas, high grade dysplasia) or cancer.
The occurrence of metachronous adenomas was assessed both as absolute and relative risks. 
Adjusted risk ratios and 95% confidence intervals (95% CI) were obtained from generalized 
linear models with age, sex, study, clinical center, treatment assignment, length of follow-up, 
and number of baseline adenomas as covariates. These models used a natural-logarithm link 
function with Poisson-distributed errors, and were adjusted for over/under-dispersion.
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We first assessed the risk of any metachronous adenomas for subjects with only proximal 
adenomas and for subjects with only distal adenomas at baseline. We repeated the analysis 
to determine the association between adenoma location at baseline and the risk for any 
metachronous advanced adenomas.
Recognizing that the presence of multiple adenomas is a known risk factor for recurrence16, 
we then restricted our analysis to patients with at two or more adenomas. We calculated the 
risk ratios for metachronous adenomas in patients with multiple proximal adenomas at 
baseline and those with bilateral adenomas at baseline using subjects with multiple 
adenomas located only distally as the reference. This analysis was repeated for 
metachronous advanced adenomas in patients with multiple adenomas at baseline.
Next, we examined whether the site of the baseline lesion was associated with the site of 
metachronous adenomas. For this analysis we included all subjects with metachronous 
adenomas. We first obtained the absolute risks of metachronous adenomas on the same side 
(ipsilateral), on the other side (contralateral) or on both sides (bilateral) by adenoma location 
at baseline. Absolute risks were compared using chi-squared test contingency table analyses.
Finally, we then computed adjusted risk ratios for patients with only proximal adenomas at 
baseline to have ipsilateral metachronous adenomas in comparison to patients with only 
distal adenomas at baseline to have ipsilateral adenomas, and similarly for metachronous 
contralateral adenomas. The analysis was repeated using metachronous advanced adenomas 
as the outcome.
Results
Of 2915 participants in the three polyp prevention trials, 2430 (83.4%) were included in this 
analysis. Excluded were subjects without a follow-up colonoscopy (n=248), missing 
information on adenoma location at baseline (n=104), at follow-up (n=110) or at both 
examinations (n=12) or subjects who only had sessile serrated adenomas at baseline by 
current diagnostic criteria (n=11). Characteristics of study participants differed moderately 
between the trials (Table 1). The mean age of participants was 59.5 years, 70.3% were men, 
and 85.6% were white. At baseline 21.5% of subjects had adenomas only in the proximal 
colon, and 52.1% only in the distal colon.
After a mean follow-up of 3.1 years, metachronous adenomas were found in 36.5% of 
subjects; 16.1% with adenomas only in the proximal colon and 13.3% only in the distal 
colon and 7.1% with adenomas in both regions. Metachronous advanced adenomas were 
found in 8.5% of subjects; in 4.8% they were located only in the proximal colon, in 3.5% 
only in the distal colon and in 0.4% in both regions.
Adenoma location and risk of metachronous adenomas
Among subjects with only proximal adenomas at baseline, 37.7% had recurrent adenomas 
compared to 28.9% for those with only distal adenomas (RR 1.17, 95% CI 1.01–1.35) 
(Figure 1). The results were similar when the analysis was restricted to subjects with 
multiple adenomas at baseline. 50.3% of subjects with multiple and only proximal adenomas 
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had metachronous adenomas, compared to 34.0% with multiple and only distal adenomas 
(RR 1.35, 95% CI 1.10–1.67). The risk for metachronous adenomas was also increased for 
subjects with adenomas on both sides, as compared to subjects with multiple adenomas only 
in the distal colon (RR 1.28, 95% CI 1.08–1.51).
The risk of metachronous adenomas was not greater for patients with proximal location of 
advanced adenomas compared to those with distal advanced adenomas at baseline (RR 1.02, 
95% CI 0.81–1.29) (Figure 1). Similarly, the risk of metachronous advanced adenomas was 
not associated with proximal location of adenomas (RR 1.12, 95% CI 0.78–1.59) or 
advanced adenomas (RR 0.83, 95% CI 0.50–1.39) at baseline (Figure 2).
Adenoma location and side of metachronous adenomas
Subjects with adenomas only in the proximal colon at baseline more often had metachronous 
adenomas in the proximal colon than in the distal colon (28.4% vs. 15.9%) (Figure 3). In 
contrast, subjects with adenomas only in the distal colon had similar risks of metachronous 
adenomas in the distal or the proximal colon (16.7% vs. 15.9% respectively). Consequently, 
subjects with only proximal adenomas at baseline had a greater risk of same side (i.e. 
ipsilateral) recurrence than subjects with only distal adenomas at baseline (RR 1.48, 95% CI 
1.22–1.80). The risk ratio remained similar when restricting the analysis to patients with 
only ipsilateral recurrence (RR 1.49, 95% CI 1.19–1.88).
When examining location and risk of metachronous advanced adenomas, we found a similar 
association. Metachronous advanced adenomas were more often detected on the same side 
as the baseline lesion. Among subjects with baseline adenomas only in the proximal colon, 
7.1% had an advanced metachronous lesion in the proximal colon, and 1.9% in the distal 
colon (Figure 4). Conversely, among subject with baseline adenomas only in the distal 
colon, 4.1% had metachronous advanced adenomas in the distal colon compared to 2.8% in 
the proximal colon. The risk for metachronous advanced adenomas to occur on the same 
side (i.e. ipsilateral) was non-significantly greater for subjects with proximal adenomas only 
at baseline as compared to those with only distal adenomas at baseline (RR 1.45, 95% CI 
0.96–2.21). The risk ratio was similar if only ipsilateral advanced adenomas were considered 
(RR 1.39, 95% CI 0.90–2.15).
Discussion
Using data from three polyp prevention trials we examined patterns of adenoma recurrence 
based on adenoma location at baseline. The study has three main findings. First, subjects 
with only proximal adenomas have a greater risk of metachronous adenomas compared to 
subjects with only distal adenomas. Second, the risk appeared to be greater if subjects had 
multiple adenomas in the proximal colon. Third, subjects with proximal adenomas were 
more likely to have metachronous adenomas on the same side (i.e. in the proximal colon) 
than subjects with distal adenomas (i.e. in the distal colon). These results support the idea 
that large bowel carcinogenesis differs by anatomic location and suggest that proximal 
adenomas portend a higher recurrence risk than distal adenomas.
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Studies have repeatedly shown that adenomas detected at a surveillance colonoscopy tend to 
be more proximal than on the baseline exam1718–2021. Few studies assessed factors 
associated with adenoma recurrence dependent on the location of the baseline lesion. 
Martinez et al. analyzed 9,167 subjects from eight polyp prevention trials, including the 
three trials used in the current analysis. The authors found a moderately increased risk of 
future non-advanced adenomas (RR 1.29; 95% CI 1.16–1.44) or advanced adenomas (RR 
1.68; 95% CI 1.43–1.98) in subjects with any proximal adenoma at baseline compared to 
subjects with adenomas only in the distal colon20. In the study by Laiyemo et al. – one of the 
eight polyp prevention trials included in the Martinez study – patients with only proximal 
adenomas were more likely to have any adenoma recurrence as compared to those with only 
distal adenomas (RR 1.14; 95% CI 1.00–1.31). Our study found a similarly small increase in 
the risk of future non-advanced adenomas for patients with proximal adenomas at baseline 
(RR 1.17, 95% CI 1.01–1.35). This effect was more pronounced if multiple proximal 
adenomas were found (relative to those with distal sided adenomas) at the baseline 
examination (RR 1.35, 95% CI 1.10–1.67). We did not find that proximal location was 
significantly associated with future advanced adenomas. This may be due to lack of power 
given the small number of advanced adenomas in our study. Alternatively, one might 
consider that initiation of adenoma growth may be associated with location, but adenoma 
growth is not.
In contrast to prior studies, we examined the strength of same side recurrence. We found that 
patients with only proximal adenomas have a greater risk of ipsilateral recurrence than 
patients with only distal adenomas at baseline. This was true for any adenoma recurrence 
(RR 1.56) and for advanced adenoma recurrence (RR=1.66). Prior observations support the 
assertion that characteristics of colorectal neoplasia differ by anatomic location. For 
instance, the serrated pathway of carcinogenesis is associated with proximal colorectal 
cancer. Proximal cancers more often express microsatellite instability, the CIMP phenotype, 
or BRAF mutations3–5 than those that are located more distally. However, our analysis 
excluded sessile serrated adenomas/polyps. The obtained results therefore suggest that risk 
for adenomatous polyps may also vary by location in the colon. This idea is supported by a 
recent study that found distinct patterns of DNA hypermethylation, independent of CIMP 
status, in proximal and distal adenomas7.
Differences in the microenvironment at the luminal-mucosal interface along the large 
intestine may contribute to varying neoplasia recurrence risk in different subsites of the 
colon. For example, from the proximal to the distal colon crypts increase in length and the 
capillary network becomes multilayered, the apoptotic index decreases, and mucin becomes 
more acidic9. Physiologically, the microbiome varies, the metabolism of secondary bile acid 
changes, the fermentation of short chain fatty acids decreases, and mutagenic metabolites 
vary8, 9. If we consider neoplasia development a complex process of interaction between 
host factors, the innate immune system, and environmental factors, changes in the 
microenvironment at the mucosal-luminal interface likely affect neoplasia risk12. Identifying 
factors that are responsible for these regional variations in adenoma risk should be the 
subject of future studies.
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An alternative explanation for the observed relative risk is a higher rate of missed adenomas 
in the proximal colon. Adenomas that were missed and not removed at index exam may add 
to adenomas found at a later colonoscopy. This may result in a higher proximal adenoma 
burden at follow-up examination. However, studies have variably reported higher miss rates 
both in the proximal colon and the distal colorectum21–23. Finally, incomplete polyp 
resection may also contribute to the observed risk difference. However, incomplete resection 
appears to be similar throughout the large bowel24.
Several limitations of our study need to be considered. First, not all risk factors for adenoma 
recurrence were considered, including smoking, obesity, and diabetes. We were unable to 
assess SSA/P at index colonoscopy, and it is now suspected that the presence of SSA/P 
might be associated with risk of adenoma recurrence25. Second, data were collected before 
the introduction of colonoscopy quality standards. Results therefore need to be confirmed 
using current standards and technology26. Third, it is conceivable that a biological change 
over time may also account for the observed changes in adenoma recurrence by location. 
However, it seems unlikely that neither advances in technology nor changes in tumor 
biology over time would have affected adenoma detection during a fairly short 3 to 4 year 
follow-up period within each trial.
The categorization of the colon into proximal and distal colorectum is based on embryonic 
origin and anatomic landmarks. Changes at the mucosal-luminal interface (morphological, 
biochemical, physiological) occur gradually along the large intestine9. Recent studies show 
that molecular characteristics of CRCs (e.g. CIMP, BRAF, MSI) also change more gradually 
from proximal to distal5, 28. The categorization into distal and proximal colon is therefore a 
simplification, and future studies should consider examining outcome measures by subsites 
of the large intestine.
In summary, proximal adenoma location was associated with a small increased risk of 
adenoma recurrence, and of adenoma recurrence on the same side as compared to distal 
adenoma location. The results may suggest different biology and disease process early in the 
adenoma-carcinoma sequence depending on anatomic location in the colon, which through a 
varying microenvironment at the luminal-mucosal interface may exert a different neoplasia 
risk. Future work more directly evaluating the contribution of specific molecular factors to 
adenoma recurrence by location within the colon is warranted.
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Figure 1. 
Metachronous adenoma risk in relation to adenoma location at baseline colonoscopy.
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Figure 2. 
Metachronous advanced adenomas in relation to adenoma location at baseline colonoscopy.
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Figure 3. 
Side of metachronous adenomas by adenoma location at baseline.
The risk ratio expresses the risk of ipsilateral (same side) recurrence for subjects with only 
proximal adenomas at baseline to have any proximal metachronous adenoma in comparison 
to subjects with only distal adenomas at baseline to have any distal metachronous adenomas.
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Figure 4. 
Side of metachronous advanced adenomas by adenoma location at baseline.
The risk ratio expresses the risk of ipsilateral (same side) recurrence for subjects with only 
proximal adenomas at baseline to have any proximal metachronous advanced adenoma in 
comparison to subjects with only distal sided adenomas at baseline to have any distal 
metachronous advanced adenomas.
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Table 1
Characteristics of Participant from the 3 Clinical Trials.
Polyp Prevention Study
Antioxidants
N (%)
Calcium
N (%)
Aspirin/Folate
N (%)
Total
N (%)
Entry characteristics
N 724 780 926 2430
Age, mean years (SD) 61.0 (8.3) 60.6 (9.0) 57.3 (9.7) 59.5 (9.2)
Sex (male) 574 (79.3) 555 (71.2) 580 (62.6) 1709 (70.3)
Race (non-white) 105 (14.6) 118 (15.1) 127 (13.7) 350 (14.4)
Location of baseline adenomas
  Distal only 383 (52.9) 392 (50.3) 491 (53.0) 1266 (52.1)
  Proximal only 108 (14.9) 141 (18.1) 273 (29.5) 522 (21.5)
  Both sides 233 (32.2) 247 (31.7) 162 (17.5) 642 (26.4)
Subjects with ≥2 adenomas, distal only 128 (17.7) 128 (16.4) 97 (10.5) 353 (14.5)
Subjects with ≥2 adenomas, proximal only 44 (6.1) 61 (7.8) 70 (7.6) 175 (7.2)
Location of baseline advanced adenomas
  Distal only 306 (42.3) 220 (28.2) 193 (20.8) 719 (29.6)
  Proximal only 56 (7.7) 44 (5.6) 55 (5.9) 155 (6.4)
  Both sides 45 (6.2) 34 (4.4) 15 (1.6) 94 (3.9)
Follow-up events
Mean follow-up, mean months (SD) 36.6 (2.7) 36.7 (3.5) 37.6 (4.1) 37.0 (3.6)
Subjects with at least one adenoma 268 (37.0) 264 (33.8) 355 (38.3) 877 (36.5)
  Distal only 105 (14.5) 77 (9.9) 140 (15.1) 322 (13.3)
  Proximal only 110 (15.2) 131 (16.8) 151 (16.3) 392 (16.1)
  Both sides 53 (7.3) 56 (7.2) 64 (6.9) 173 (7.1)
 Subjects with advanced adenomas (%) 64 (8.8) 64 (8.2) 82 (8.5) 210 (8.5)
  Distal only 30 (4.1) 20 (2.6) 34 (3.7) 84 (3.5)
  Proximal only 30 (4.1) 41 (5.3) 45 (4.9) 116 (4.8)
  Both sides 4 (0.6) 3 (0.4) 3 (0.3) 10 (0.4)
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